The new rosiglitazone story: its place today in type 2 diabetes management.
Prim Care Diabetes
; 3(1): 57-9, 2009 Feb.
Article
em En
| MEDLINE
| ID: mdl-19269912
ABSTRACT
ADOPT suggests that rosiglitazone, ahead of traditional therapies, can meet patient needs with respect to long-term glycaemic control, yet the recent safety debate, stimulated by retrospective meta-analysis, has seriously affected physician confidence to use it. Other recent evidence, including from a number of long-term outcome studies, does not confirm or exclude a cardiovascular risk signal for rosiglitazone, and evaluation of this data has led EMEA to support continued use of rosiglitazone, albeit with a recommendation not to use in patients with a previous cardiovascular history. Where does this leave us? Rosiglitazone remains the only oral blood glucose lowering agent to have demonstrated nearly 5 years of blood glucose control. Patients earlier in their disease, free of known cardiovascular disease, are just the patients to benefit most from long term glucose target achievement.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tiazolidinedionas
/
Diabetes Mellitus Tipo 2
/
Hipoglicemiantes
Tipo de estudo:
Etiology_studies
/
Guideline
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Prim Care Diabetes
Assunto da revista:
ENDOCRINOLOGIA
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Reino Unido